Slide 1: Third Quarter 2022 Earnings Presentation
ANGIODYNAMICS Third Quarter 2022 Earnings PresentationApril 7, 2022 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q3 and YTD Highlights
Corporate Developments – Q3 and YTD Highlights 3 Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombectomy & NanoKnife Revised FY2021 Guidance 3 FY22 Guidance Revenue(unchanged) Adjusted EPS(unchanged) Gross Margin(unchanged) $310 - $315 million COVID-19 related headwinds pe
Slide 4: Q3 and YTD Highlights: Financial Performance
Third Quarter and YTD Highlights Q3 FY2022 Q3 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $73,970 $71,182 3.9% $229,221 $214,168 7.0% Gross Margin 52.2% 54.1% (190 bps) 52.0% 53.4% (140 bps) Net Loss ($4,958) ($3,544) ($1,414) ($20,281) ($12,080) ($8,201) GAAP EPS ($0.13) ($0.09) ($0.04) ($0.
Slide 5: Q3 and YTD Highlights: Med Tech and Med Device Revenue
Third Quarter and YTD Highlights 5 Med Device Med Tech $10.5 $17.6 $59.7 $59.4 28.6% growth 2.8% decline Q3 Revenue Growth Q3 FY21 Q3 FY22 YTD Revenue Contribution Med Device Med Tech YTD FY21 YTD FY22 41.8% growth 0.8% decline Q3 Revenue Contribution YTD Revenue Growth 15.2 19.6 54.4
Slide 6: Highlights – Sales Growth Over Prior Periods
Third Quarter Highlights – Sales Growth Over Prior Periods Endovascular Therapies Q3 FY2022 YTD FY2022 Auryon 117% 199% Mechanical Thrombectomy* 14% 18% Thrombolytics (19%) (13%) Core Peripheral 2% 7% Venous Insufficiency 0% 0% Vascular Access Q3 FY2022 YTD FY2022 Midlines (11%) (21%) C3 8% 20% PICC
Slide 7: Q3 and YTD FY2022 Results (unaudited)
Third Quarter and YTD FY2022 Results (unaudited) $ in thousands (except per share data) Q3 FY2022 Q3 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $73,970 $71,182 3.9% $229,221 $214,168 7.0% Med Tech Med Device $19,612$54,358 $15,246$55,936 28.6%(2.8%) $56,117$173,104 $39,581$174,587 41.8%(0.8%
Slide 8: Third Quarter FY22 Gross Margin Bridge
8 Third Quarter FY22 Gross Margin Bridge
Slide 9: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 9
Slide 10: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to re